Drug name - Xtandi

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7709517 ASTELLAS Diarylhydantoin compounds
Aug, 2027

(4 years from now)

CN102584712A ASTELLAS Diaryl Hydantoin Compound
Nov, 2015

(6 years ago)

CN105037273B ASTELLAS Diaryl Hydantoin Compound
Mar, 2026

(3 years from now)

CN101222922A ASTELLAS Diarylhydantoin Compounds
Mar, 2026

(3 years from now)

CN101222922B ASTELLAS Diaryl Hydantoin Compounds
Mar, 2026

(3 years from now)

CN105037273A ASTELLAS Diaryl Hydantoin Compound
Mar, 2026

(3 years from now)

CN102755318A ASTELLAS Diaryl Thiohydantoin Compounds
Mar, 2027

(4 years from now)

CN102755318B ASTELLAS Diarylthiohydantoin Compound
Mar, 2027

(4 years from now)

CN101460467A ASTELLAS Diarylthiohydantoin Compounds
Mar, 2027

(4 years from now)

CN101460467B ASTELLAS Diarylthiohydantoin Compound
Mar, 2027

(4 years from now)

EP2444085A1 ASTELLAS Diarylhydantoin Compounds As Androgen Receptor Antagonists For Treatment Of Cancer
Jun, 2016

(6 years ago)

EP2444085B1 ASTELLAS Diarylhydantoin Compounds As Androgen Receptor Antagonists For Treatment Of Cancer
Jun, 2016

(6 years ago)

EP1893196B2 ASTELLAS Diarylhydantoin Compound
Mar, 2026

(3 years from now)

EP1893196A1 ASTELLAS Diarylhydantoin Compound
Mar, 2026

(3 years from now)

EP1893196B1 ASTELLAS Diarylhydantoin Compound
Mar, 2026

(3 years from now)

EP1893196A4 ASTELLAS Diarylhydantoin Compounds
Mar, 2026

(3 years from now)

EP2656842A3 ASTELLAS Androgen Receptor Modulator For The Treatment Of Prostate Cancer And Androgen Receptor-Associated Diseases
Mar, 2027

(4 years from now)

EP2013187A2 ASTELLAS Diarylthiohydantoin Compounds
Mar, 2027

(4 years from now)

EP2013187B1 ASTELLAS Diarylthiohydantoin Compounds
Mar, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9126941 ASTELLAS Treatment of hyperproliferative disorders with diarylhydantoin compounds May, 2026

(3 years from now)

US8183274 ASTELLAS Treatment of hyperproliferative disorders with diarylhydantoin compounds Aug, 2026

(3 years from now)

Drugs and Companies using ENZALUTAMIDE ingredient

Treatment: Treatment of patients with castration-resistant prostate cancer (crpc); the treatment of patients with metastatic castration-resistant prostate cancer (crpc).; the treatment of patients with metastatic castration-sensitive prostate cancer; The treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel; the treatment of patients with metastatic castration-resistant prostate cancer (crpc).; the treatment of patients with metastatic castration-sensitive prostate cancer; treatment of patients with castration-resistant prostate cancer (crpc)

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
40MG TABLET;ORAL Prescription
80MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.